Lumida
/AIRS
⌘K
AirSculpt Technologies Inc

AirSculpt Technologies Inc

AIRS
$4.45USD↑+6.97%+0.29 today

MARKET CAP

313.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$4 – $5

52W RANGE

$2
$12

AI Summary

Stalk
StalkMedium

In Stage 2 Advancing, AIRS retains a medium-term bullish bias underpinned by higher highs/lows and support at the rising 50 DMA, but short-term timing is neutral as price pulls back into the 9/21/50 EMA zone. Execution should be deferred around this support range, seeking evidence of acceptance before committing. Primary risk is a decisive break below the 50 DMA and prior higher-low, which would invalidate the bullish outlook.

  • ↑GLP-1 meds could grow patient base from 5M to 25M by 2030, with 63% intent (~19M patients).
  • ↑Q1 revenue $39.4M (+19% sequential; flat YoY) with same-center sales up 1%.
  • ↓Negative earnings yield and significant revisions signal underlying operational weakness.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

AirSculpt Technologies, Inc. (NASDAQ: AIRS) specializes in minimally invasive body contouring procedures, operating within the rapidly growing aesthetic medical service sector. The company is strategically positioned to benefit from the burgeoning market influenced by GLP-1 medications, which are significantly impacting consumer demand for aesthetic enhancements. With a focus on innovative procedures and an expanding service offering, AirSculpt aims to capitalize on new patient demographics, driving both growth and market penetration in a competitive landscape.

Bull says

  • ↑GLP-1 meds could grow patient base from 5M to 25M by 2030, with 63% intent (~19M patients).
  • ↑Q1 revenue $39.4M (+19% sequential; flat YoY) with same-center sales up 1%.
  • ↑Debt reduced by $11M to $46M, maintaining covenant compliance and on track to refinance.
  • ↑Adjusted EBITDA of $3.3M (8.4% margin) and $5M operating cash flow indicate recovery.
  • ↑Book-to-price at 0.86 and positive free cash flow suggest possible undervaluation.
  • ↑Consensus “Reduce” P/E of –25.15 offers upside if efficiencies boost results.

Bear says

  • ↓Negative earnings yield and significant revisions signal underlying operational weakness.
  • ↓Adjusted EBITDA margin fell from 9.5% to 8.4%; customer acquisition costs at $3,400 per case.
  • ↓Consumer hesitance persists, limiting revenue despite GLP-1 tailwinds.
  • ↓Gross debt of $46M and leverage pose refinancing and covenant compliance risks.
  • ↓High short interest (0.59) and consensus “Reduce” rating reflect market skepticism.
  • ↓Weak profitability factors and elevated volatility underscore downside risk.

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-09-2026bullish

Transcript signals

Bull points

  • Thank you for joining us to discuss Airscope Technologies results for the first quarter of fiscal year 2026.
  • We are very pleased with our start to 2026 and the momentum we continue to see in Q2.
  • Cost of services was $15.6 million, resulting in gross margin expansion of roughly 1% to 60% of revenue.

Bear points

  • Customer acquisition costs for the quarter is roughly $3,400 per case, compared to $3,130 in the prior year quarter.
  • Adjusted EBITDA was $3.3 million, or roughly 8.4% of revenue, a decrease from 9.5% in the prior year.
Read full transcript analysis ›